{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:00:56Z","timestamp":1791856856298,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"DOI":"10.7759\/cureus.97974","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T02:21:43Z","timestamp":1764296503000},"source":"Crossref","is-referenced-by-count":2,"title":["Impaired Human Papillomavirus (HPV) Clearance in a Patient on Upadacitinib for Atopic Dermatitis: A Case of Refractory Genital Warts Resolved After Drug Withdrawal"],"prefix":"10.7759","author":[{"given":"Norifumi","family":"Kennoki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyotaro","family":"Nohata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Nakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Centers for Disease Control and Prevention. Anogenital warts \u2014 STI treatment guidelines. (2021). https.\/\/www.cdc.gov\/std\/treatment-guidelines\/anogenital-warts.htm."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30 Suppl 5","author":"Doorbar J","year":"2012","unstructured":"Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-cycle of human papillomaviruses. Vaccine. 2012, 30 Suppl 5:F55-70. 10.1016\/j.vaccine.2012.06.083","journal-title":"Vaccine"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.1.25","article-title":"Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus","volume":"134","author":"Edwards L","year":"1998","unstructured":"Edwards L, Ferenczy A, Eron L, et al.. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol. 1998, 134:25-30. 10.1001\/archderm.134.1.25","journal-title":"Arch Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2007.007196","article-title":"Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts","volume":"19","author":"Stefanaki C","year":"2008","unstructured":"Stefanaki C, Katzouranis I, Lagogianni E, et al.. Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts. Int J STD AIDS. 2008, 19:441-4. 10.1258\/ijsa.2007.007196","journal-title":"Int J STD AIDS"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-1-3","article-title":"Imiquimod for the treatment of genital warts in adults: a systematic review and meta analysis of randomized controlled trials","volume":"2899","author":"Moore RA","year":"2001","unstructured":"Moore RA, Edwards JE, Hopwood J, et al.. Imiquimod for the treatment of genital warts in adults: a systematic review and meta analysis of randomized controlled trials. Cochrane Database Syst Rev. 2001, 2899:10.1186\/1471-2334-1-3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02906.x","article-title":"Human papillomavirus infection in solid organ transplant recipients.","volume":"9(Suppl 4)","author":"Kwak EJ","year":"2009","unstructured":"Kwak EJ, Julian K, AST Infectious Diseases Community of Practice.. Human papillomavirus infection in solid organ transplant recipients.. Am J Transplant. 2009, 9(Suppl 4):S151-S160. 10.1111\/j.1600-6143.2009.02906.x","journal-title":"Am J Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.","volume":"397","author":"Guttman-Yassky E","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al.. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.. Lancet. 2021, 397:2151-68. 10.1016\/S0140-6736(21)00588-2","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu Q","year":"2023","unstructured":"Xu Q, He L, Yin Y.. Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. Front Pharmacol. 2023, 14:1241954. 10.3389\/fphar.2023.1241954","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed MF","year":"2023","unstructured":"Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2023, 17:e13688. 10.1111\/cts.13688","journal-title":"Clin Transl Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier JM","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et al.. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018, 2:23. 10.1186\/s41927-018-0031-x","journal-title":"BMC Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.04.019","article-title":"Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis","volume":"36","author":"Seale E","year":"2023","unstructured":"Seale E, Gavigan G.. Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis. JAAD Case Rep. 2023, 36:60-62. 10.1016\/j.jdcr.2023.04.019","journal-title":"JAAD Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/762035","article-title":"Eruptive condyloma accuminata after initiation of infliximab treatment for folliculitis decalvans","volume":"2013","author":"Wu DC","year":"2013","unstructured":"Wu DC, Salopek TG. Eruptive condyloma accuminata after initiation of infliximab treatment for folliculitis decalvans. Case Rep Dermatol Med. 2013, 2013:762035. 10.1155\/2013\/762035","journal-title":"Case Rep Dermatol Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(99)00033-9","article-title":"Enhancement of the innate and cellular immune response in patients with genital warts treated with imiquimod","volume":"43","author":"Arany I","year":"1999","unstructured":"Arany I, Tyring SK. Enhancement of the innate and cellular immune response in patients with genital warts treated with imiquimod. Antiviral Res. 1999, 43:55-63. 10.1016\/S0166-3542(99)00033-9","journal-title":"Antiviral Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi H","year":"2002","unstructured":"Hemmi H, Kaisho T, Takeuchi O, et al.. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002, 3:196-200. 10.1038\/ni758","journal-title":"Nat Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.22.14355-14370.2005","article-title":"The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques","volume":"79","author":"Wang Y","year":"2005","unstructured":"Wang Y, Abel K, Lantz K, Krieg AM, McChesney MB, Miller CJ. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol. 2005, 79:14355-70. 10.1128\/JVI.79.22.14355-14370.2005","journal-title":"J Virol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389020-impaired-human-papillomavirus-hpv-clearance-in-a-patient-on-upadacitinib-for-atopic-dermatitis-a-case-of-refractory-genital-warts-resolved-after-drug-withdrawal","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T02:21:45Z","timestamp":1764296505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389020-impaired-human-papillomavirus-hpv-clearance-in-a-patient-on-upadacitinib-for-atopic-dermatitis-a-case-of-refractory-genital-warts-resolved-after-drug-withdrawal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.97974","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}